Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
about
Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIVSynthetic DNA vaccine strategies against persistent viral infectionsThe enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathwayPriming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesHuman immunodeficiency virus vaccine trialsPotential effect of prior raccoonpox virus infection in raccoons on vaccinia-based rabies immunization.A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolatesRecombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in MacaquesPolyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.Cytotoxic and proliferative T cell responses in HIV-1-infected Macaca nemestrina.A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in ChinaInduction of immunity to human immunodeficiency virus type-1 by vaccination.Non-human primate models for AIDS vaccine research.Immunogenicity and protection studies with recombinant mycobacteria and vaccinia vectors coexpressing the 18-kilodalton protein of Mycobacterium lepraeVaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.Extracellular vaccinia virus envelope glycoprotein encoded by the A33R geneDetection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination.Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicityClade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteersLessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responsesEnhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 ProteinsPhase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialSafety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 studyEvaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1.Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccineOral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in MacaquesA new era in HIV vaccine development.Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity.Genetically engineered poxviruses for recombinant gene expression, vaccination, and safetyInduction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.Advances in antiviral vaccine development.Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.
P2860
Q24797123-0AD44EE7-87E1-4BAE-A81F-54A6ADF99CC3Q27016078-176165E7-B329-450F-B54E-FFB5EA20A137Q28306549-07DBA0A8-A03E-4839-B1FE-458D69CBAC5BQ28749120-2F90FA34-0950-4509-B824-5D484407CBA7Q30424366-869BA96C-4FD4-4C8B-9D27-6E3BBA209B73Q33373833-057CCE0C-4AA9-4143-833F-AB853881B84CQ33603494-F844D21C-B7C6-48EE-AC64-251B8C16519EQ33782797-22DCA011-F4A5-43F7-881E-15D196F46C68Q33786257-F4F11A47-016D-4DF3-A599-0B269F5B564DQ33800760-DF4738B1-9106-4937-B933-141E39804E6AQ33819493-A24865CD-4830-471B-9D73-2642311EEE85Q33850605-4D55848F-0953-48E7-BEAF-7A235DC3B76FQ34194927-476043B3-0DC4-4159-AA82-44DE8433084EQ34206208-8E6C2CC8-9FBE-459D-AD71-7C4B3813EA03Q34540645-D48CBC2E-B61D-456C-80B6-CACB94304CA6Q34715769-46C5A5E2-EC0E-41CE-A3D4-C70C93BC5DFEQ35499788-7BFAB4C9-A9C2-47B1-BC6F-D10E9D57C578Q35848078-A9E4539B-10CC-4FFF-B6B1-BB313AB12380Q35861514-084F7831-0143-47A0-8671-C93FFE0AA6FBQ35865606-8CCFF6C0-1DF1-488F-A551-6397BE0977CAQ35886254-32E147DA-53A1-450B-9028-05F86D343963Q35895851-3E886B90-CC9B-4750-AF03-BDF04889DD70Q35896058-6064B0B3-6B08-42B8-9735-71731F35C244Q35997008-41279913-74C1-4ECF-8C23-42F1DF6DC7A2Q36009232-638ED0D3-921F-4512-9E2B-EA7182E04221Q36424574-CC21EA42-92D3-4307-82C3-C23EA046104DQ36481537-04442DDE-BDB5-49E9-AD17-D74774869ED0Q36618096-DF369771-68A4-4ACC-8399-3DDA611A261EQ36621905-2BDE4DEC-F640-41F5-A9EF-C878746F0B2AQ36625106-D40107CA-0EF6-4ADE-B062-E572E17216A5Q36633526-4FAE136D-BCAC-4AFE-B464-BADF5F24B59AQ36665647-A61ABEF7-ABB0-4A5D-9060-02703D9224C9Q36777835-9CCDD541-216C-41E7-A60D-811A5D43D4B1Q37032195-AEC6AF7E-7466-45D3-8233-2B96192B1C2CQ37249251-6854E7D3-A1B9-42B4-9A57-EF5AFD7264BDQ37252966-6D87EAC7-3858-43C7-8E40-15E06C59DB0DQ37292398-09983037-B60D-446A-BF22-97D8158D212AQ37625485-0BBE5B07-E257-4E42-940E-50B3EEFE7218Q37785949-4ED7BDAE-851E-4774-B51D-57F1E5EA985AQ38748193-EA5789BB-A9A2-44E4-BC5D-4083CCEBA3BC
P2860
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Enhanced immunity to human imm ...... nd boosting with gp160 protein
@ast
Enhanced immunity to human imm ...... nd boosting with gp160 protein
@en
type
label
Enhanced immunity to human imm ...... nd boosting with gp160 protein
@ast
Enhanced immunity to human imm ...... nd boosting with gp160 protein
@en
prefLabel
Enhanced immunity to human imm ...... nd boosting with gp160 protein
@ast
Enhanced immunity to human imm ...... nd boosting with gp160 protein
@en
P2093
P2860
P356
P1476
Enhanced immunity to human imm ...... nd boosting with gp160 protein
@en
P2093
A C Collier
E L Cooney
P D Greenberg
R W Coombs
P2860
P304
P356
10.1073/PNAS.90.5.1882
P407
P577
1993-03-01T00:00:00Z